株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血友病の世界市場分析:タイプ(血友病A、血友病B、血友病C)、処置(オンデマンド補充療法、定期的補充療法)、治療法別(補充療法、遺伝子治療)別

Hemophilia Market Size, Share & Trends Analysis Report By Type (Type A, Type B, Type C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, Gene Therapy), By Region, And Segment Forecasts, 2020 - 2027

発行 Grand View Research, Inc. 商品コード 368045
出版日 ページ情報 英文 90 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.54円で換算しております。
血友病の世界市場分析:タイプ(血友病A、血友病B、血友病C)、処置(オンデマンド補充療法、定期的補充療法)、治療法別(補充療法、遺伝子治療)別 Hemophilia Market Size, Share & Trends Analysis Report By Type (Type A, Type B, Type C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, Gene Therapy), By Region, And Segment Forecasts, 2020 - 2027
出版日: 2020年03月13日 ページ情報: 英文 90 Pages
概要

世界の血友病市場は、2026年までに169億米ドル規模の市場に成長すると予測されています。予防的治療を実施するために行われる対象集団の診断の必要性の高まりや、政府の血友病支援プログラムなどが当市場の成長を促進しています。

当レポートでは、世界の血友病市場を調査し、市場の概要、タイプ・処置・治療法・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場シェア、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査方法と範囲

  • 市場区分と範囲
  • 情報調達
  • 情報分析
  • 市場構成とデータの可視化
  • データ検証と公開

第2章 エグゼクティブサマリー

  • 市場の見通し
  • 市場の見通し:セグメント別
  • 競争洞察

第3章 市場変数・傾向・範囲

  • 市場の見通し
  • 浸透および成長の見通し
  • パイプライン分析:治験段階別
  • 利用者観点の分析
  • 主要エンドユーザー:製品・地域/国別
  • 規制の枠組み
  • 市場力学
  • 市場分析ツール

第4章 世界の血友病市場の分析:タイプ別

  • 定義と範囲
  • 市場シェアの分析:タイプ別(実績値・予測値)
  • セグメントダッシュボード
  • 世界の血友病市場:タイプ別
  • 市場規模の推移と予測:タイプ別
    • 血友病 A
    • 血友病 B
    • 血友病 C
    • その他

第5章 世界の血友病市場の分析:治療法別

  • 定義と範囲
  • 市場シェアの分析:治療法別(実績値・予測値)
  • セグメントダッシュボード
  • 世界の血友病市場:治療法別
  • 市場規模の推移と予測:治療法別
    • 補充療法
    • 免疫寛容導入療法
    • 遺伝子療法

第6章 世界の血友病市場の分析:処置別

  • 定義と範囲
  • 市場シェアの分析:処置別(実績値・予測値)
  • セグメントダッシュボード
  • 世界の血友病市場:処置別
  • 市場規模の推移と予測:処置別
    • オンデマンド補充療法(出血時補充療法)
    • 定期的補充療法

第7章 世界の血友病市場の分析:地域別

  • 定義と範囲
  • 市場シェアの分析:地域別(実績値・予測値)
  • セグメントダッシュボード
  • 市場スナップショット
  • 市場シェア & 主要企業:地域別
  • SWOT分析:地域別
  • 市場規模の推移と予測:地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ

第8章 競合分析

  • 主要参入企業の近年の動向と影響分析
  • 企業区分(イノベーター・マーケットリーダー・新興企業)
  • ベンダー情勢
  • 公開会社
  • 民間企業
  • サプライヤーランキング
  • 主要企業のプロファイル
    • Novo Nordisk
    • Biogen.
    • 中外製薬
    • Bayer Healthcare
    • Pfizer.
    • Shire Plc
    • Baxalta (Baxter Healthcare)
    • CSL Behring.
    • Octapharma

第9章 キーオピニオンリーダーの解説

第10章 提言

図表

List of Tables

  • TABLE 1 List of Abbreviation
  • TABLE 2 North America Hemophilia Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 3 North America Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 4 North America Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 5 North America Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 6 U.S. Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 7 U.S. Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 8 U.S. Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 9 Canada Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 10 Canada Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 11 Canada Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 12 Europe Hemophilia Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 13 Europe Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 14 Europe Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 15 Europe Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 16 U.K. Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 17 U.K. Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 18 U.K. Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 19 Germany Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 20 Germany Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 21 Germany Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 22 France Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 23 France Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 24 France Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 25 Italy Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 26 Italy Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 27 Italy Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 28 Spain Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 29 Spain Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 30 Spain Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 31 Asia Pacific Hemophilia Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 32 Asia Pacific Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 33 Asia Pacific Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 34 Asia Pacific Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 35 Japan Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 36 Japan Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 37 Japan Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 38 China Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 39 China Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 40 China Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 41 India Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 42 India Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 43 India Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 44 South Korea Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 45 South Korea Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 46 South Korea Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 47 Australia Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 48 Australia Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 49 Australia Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 50 Latin America Hemophilia Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 51 Latin America Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 52 Latin America Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 53 Latin America Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 54 Mexico Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 55 Mexico Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 56 Mexico Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 57 Brazil Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 58 Brazil Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 59 Brazil Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 60 Argentina Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 61 Argentina Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 62 Argentina Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 63 Columbia Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 64 Columbia Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 65 Columbia Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 66 MEA Hemophilia Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 67 MEA Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 68 MEA Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 69 MEA Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 70 South Africa Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 71 South Africa Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 72 South Africa Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 73 Saudi Arabia Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 74 Saudi Arabia Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 75 Saudi Arabia Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 76 UAE Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 77 UAE Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 78 UAE Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Market summary
  • FIG. 4 Market segmentation & scope
  • FIG. 5 Market size and growth prospects
  • FIG. 6 Global hemophilia market- Key market driver analysis
  • FIG. 7 Global hemophilia market - Key market restraint analysis
  • FIG. 8 Penetration & growth prospect mapping
  • FIG. 9 Global hemophilia market - Porter's analysis
  • FIG. 10 Global hemophilia market - PESTEL analysis
  • FIG. 11 Global hemophilia market type outlook key takeaways
  • FIG. 12 Global hemophilia market: Type movement analysis
  • FIG. 13 Hemophilia A market estimates, 2016 - 2027 (USD Million)
  • FIG. 14 Hemophilia B market estimates, 2016 - 2027 (USD Million)
  • FIG. 15 Hemophilia C market estimates, 2016 - 2027 (USD Million)
  • FIG. 16 Others market estimates, 2016 - 2027 (USD Million)
  • FIG. 17 Global hemophilia market treatment outlook key takeaways
  • FIG. 18 Global hemophilia market: Treatment movement analysis
  • FIG. 19 On-demand market estimates, 2016 - 2027 (USD Million)
  • FIG. 20 Prophylaxis market estimates, 2016 - 2027 (USD Million)
  • FIG. 21 Global hemophilia market therapy outlook key takeaways
  • FIG. 22 Global hemophilia market: Therapy movement analysis
  • FIG. 23 Replacement therapy market estimates, 2016 - 2027 (USD Million)
  • FIG. 24 ITI therapy market estimates, 2016 - 2027 (USD Million)
  • FIG. 25 Gene therapy market estimates, 2016 - 2027 (USD Million)
  • FIG. 26 Regional marketplace: Key takeaways
  • FIG. 27 Global hemophilia market: Regional movement analysis
  • FIG. 28 North America hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 29 U.S. hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 30 Canada hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 31 Europe hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 32 U.K. hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 33 Germany hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 34 France hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 35 Spain hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 36 Italy hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 37 Asia Pacific hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 38 Japan hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 39 China hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 40 India hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 41 South Korea hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 42 Australia hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 43 Latin America hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 44 Brazil hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 45 Mexico hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 46 Argentina hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 47 Colombia hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 48 MEA hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 49 South Africa hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 50 Saudi Arabia hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 51 UAE market, 2016 - 2027 (USD Million)
  • FIG. 52 Strategy framework
目次
Product Code: 978-1-68038-989-0

The global hemophilia market size is expected to reach USD 18.1 billion by 2027, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 5.5% over the forecast period. Increasing awareness of early diagnosis and treatment coupled with supportive government policies is anticipated to boost market share over the forecast period.

For instance, the NHF (National Hemophilia Foundation) allows to find treatments for inheritable bleeding disorders and help prevent complications of these disorders through research, education, and advocacy. Their programs and initiatives are in association with the Centers for Disease Control and Prevention.

In addition, U.S. Hemophilia Treatment Center Network provides specialized healthcare centers and these offer care to address all psychological, educational, and physical needs of patients suffering from the disease. These centers currently provide care to more than 35,000 adults and children with the disease and other bleeding disorders.

The key market companies are projected to adopt strategic initiatives including geographic expansion and R&D especially in developing and underdeveloped regions, such as Middle Eastern and West African countries.

For instance, BioMarin is involved in developing Valoctocogene Roxaparvovec (BMN-270) for treating type A patients and is currently under clinical trials. Furthermore, in June 2017, the U.S. FDA accepted the investigational new drug application for Sanofi's BIVV001 based on its preclinical study results.

Rising incidence of the disease is estimated to propel hemophilia market growth over the forecast period. According to the data published by the NHF, around 20,000 individuals in U.S. are suffering from this disease. In addition, approximately 75% of people with hemophilia receive inadequate treatment or have less/ no access to treatment globally.

Further key findings from the report suggest:

Hemophilia A held the largest market share in 2019 due to its increasing prevalence worldwide

Type B is expected to be the fastest growing type over the forecast period, at a CAGR of 6.8%

On-demand dominated the treatment segment over the forecast period and is expected to contribute majority of the share in 2019

Prophylaxis is estimated to be the fastest growing segment over the forecast period

Replacement therapy was expected to be the largest segment in 2019

Gene therapy dominated the therapy segment over the forecast period owing to increasing involvement of companies to develop more gene therapy for its treatment

Increasing research and development and strategic collaborations are key strategies undertaken by major players in the market space.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market segmentation & scope
  • 1.2. Information procurement
    • 1.2.1. Purchased database
    • 1.2.2. GVR's internal database
    • 1.2.3. Secondary sources & third party perspectives
    • 1.2.4. Primary research
  • 1.3. Information analysis
    • 1.3.1. Data analysis models
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Hemophilia Market Variables, Trends & Scope

  • 3.1. Market Lineage outlook
    • 3.1.1. Parent/ Ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Product Pipeline Analysis
  • 3.4. Regulation Framework
  • 3.5. Market Dynamics
    • 3.5.1. Market Driver Analysis
      • 3.5.1.1. Increasing population of newborns
      • 3.5.1.2. Favorable government initiative
      • 3.5.1.3. Rising R&D and new product development
      • 3.5.1.4. Rising adoption for prophylaxis treatment
    • 3.5.2. Market Restraint Analysis
      • 3.5.2.1. High cost associated to procure treatment
  • 3.6. Hemophilia: Market Analysis Tools
    • 3.6.1. Industry Analysis - Porter's
      • 3.6.1.1. Supplier Power: Moderate due to presence of suppliers in the market
      • 3.6.1.2. Buyer Power: Low due to high cost of the treatment
      • 3.6.1.3. Substitution Threat: High due to presence of internal substitutes
      • 3.6.1.4. Threat from new entrant: Moderate due to presence of strong global presence of existing players
      • 3.6.1.5. Competitive rivalry: High due to involvement of companies into developing novel therapies
    • 3.6.2. PESTEL Analysis
      • 3.6.2.1. Political Landscape
      • 3.6.2.2. Environmental Landscape
      • 3.6.2.3. Social Landscape
      • 3.6.2.4. Technology Landscape
      • 3.6.2.5. Legal Landscape
    • 3.6.3. Major Deals & Strategic Alliances Analysis
      • 3.6.3.1. Joint Ventures
      • 3.6.3.2. Mergers & Acquisitions
      • 3.6.3.3. Licensing & Partnership
      • 3.6.3.4. Technology Collaborations
      • 3.6.3.5. Strategic Divestments

Chapter 4. Hemophilia Market: Segment Analysis, By Type, 2016 - 2027 (USD Million)

  • 4.1. Definitions & Scope
  • 4.2. Type market share analysis, 2019 & 2027
  • 4.3. Segment Dashboard
  • 4.4. Global Hemophilia Market, By Type, 2016 to 2027
  • 4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
    • 4.5.1. Hemophilia A
    • 4.5.2. Hemophilia B
    • 4.5.3. Hemophilia C
    • 4.5.4. Others

Chapter 5. Hemophilia market: Segment Analysis, By Treatment, 2016 - 2027 (USD Million)

  • 5.1. Definitions & Scope
  • 5.2. Treatment market share analysis, 2019 & 2027
  • 5.3. Segment Dashboard
  • 5.4. Global Hemophilia Market, By Treatment, 2016 to 2027
  • 5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
    • 5.5.1. On- demand
    • 5.5.2. Prophylaxis

Chapter 6. Hemophilia market: Segment Analysis, By Therapy, 2016 - 2027 (USD Million)

  • 6.1. Definitions & Scope
  • 6.2. Therapy market share analysis, 2019 & 2027
  • 6.3. Segment Dashboard
  • 6.4. Global Hemophilia Market, By Therapy, 2016 to 2027
  • 6.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
    • 6.5.1. Replacement therapy
    • 6.5.2. Gene therapy
    • 6.5.3. ITI therapy

Chapter 7. Hemophilia market: Regional Market Analysis, By Region, 2016 - 2027 (USD Million)

  • 7.1. Definitions & Scope
  • 7.2. Regional market share analysis, 2019 & 2027
  • 7.3. Regional Market Dashboard
  • 7.4. Regional Market Share and Leading Players, 2019
  • 7.5. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
    • 7.5.1. North America
    • 7.5.2. Europe
    • 7.5.3. Asia Pacific
    • 7.5.4. Latin America
    • 7.5.5. Middle East & Africa
  • 7.6. Market Size, & Forecasts and Trend Analysis
  • 7.7. North America
    • 7.7.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.7.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
    • 7.7.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
    • 7.7.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.7.5. U.S.
      • 7.7.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.7.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.7.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.7.6. Canada
      • 7.7.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.7.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.7.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
  • 7.8. Europe
    • 7.8.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.8.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
    • 7.8.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
    • 7.8.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.8.5. Germany
      • 7.8.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.8.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.8.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.8.6. U.K.
      • 7.8.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.8.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.8.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.8.7. France
      • 7.8.7.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.8.7.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.8.7.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.8.8. Italy
      • 7.8.8.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.8.8.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.8.8.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.8.9. Spain
      • 7.8.9.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.8.9.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.8.9.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
  • 7.9. Asia Pacific
    • 7.9.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.9.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
    • 7.9.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
    • 7.9.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.9.5. China
      • 7.9.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.9.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.9.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.9.6. Japan
      • 7.9.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.9.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.9.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.9.7. India
      • 7.9.7.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.9.7.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.9.7.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.9.8. Australia
      • 7.9.8.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.9.8.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.9.8.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.9.9. South Korea
      • 7.9.9.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.9.9.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.9.9.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
  • 7.10. Latin America
    • 7.10.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.10.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
    • 7.10.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
    • 7.10.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.10.5. Brazil
      • 7.10.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.10.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.10.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.10.6. Mexico
      • 7.10.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.10.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.10.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.10.7. Argentina
      • 7.10.7.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.10.7.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.10.7.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.10.8. Colombia
      • 7.10.8.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.10.8.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.10.8.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
  • 7.11. Middle East and Africa
    • 7.11.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.11.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
    • 7.11.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
    • 7.11.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.11.5. South Africa
      • 7.11.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.11.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.11.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.11.6. Saudi Arabia
      • 7.11.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.11.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.11.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.11.7. UAE
      • 7.11.7.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.11.7.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.11.7.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)

Chapter 8. Hemophilia market - Competitive Analysis

  • 8.1. Recent developments & impact analysis, by key market participants
  • 8.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
  • 8.3. Public Companies
    • 8.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 8.3.2. Company Market Share/Ranking, by region
    • 8.3.3. Competitive Dashboard Analysis
  • 8.4. Private Companies
    • 8.4.1. List of key emerging companies/technology disruptors/innovators
    • 8.4.2. Regional network map
    • 8.4.3. Company market position analysis
  • 8.5. Key companies profiles
    • 8.5.1. Novo Nordisk A/S
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Shire
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Chugai Pharmaceutical Co. Ltd.
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Bayer AG
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Pfizer, Inc.
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. CSL Behring
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. BioMarin
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Octopharma AG
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Genzyme Corporation
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Spark Therapeutics, Inc.
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives